Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ELANE | P08246 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29549519 | 1.00 | CYP2C19 (1.00) | CYP2C19TDP1LMNATSHRHDAC6 | |
| SCHEMBL3658950 | 0.90 | CYP2C19 (0.82) | CYP2C19TDP1LMNATSHRHDAC6 | |
| SCHEMBL4115493 | 0.86 | TDP1 (0.78) | CYP2C19TDP1LMNATSHRHDAC6 | |
| SCHEMBL3658948 | 0.86 | CYP2C19 (0.74) | CYP2C19TDP1LMNATSHRHDAC6 | |
| SCHEMBL10245818 | 0.79 | CYP2C19 (0.66) | CYP2C19TDP1LMNATSHRKMT2A | |
| SCHEMBL11483696 | 0.78 | CYP2C19 (0.64) | CYP2C19TDP1LMNATSHRKMT2A | |
| SCHEMBL15461433 | 0.78 | CNR1 (0.80) | CYP2C19TDP1KMT2ACNR1 | |
| Mephenytoin SCHEMBL21768 | 0.78 | CYP2C19 (1.00) | CYP2C19TDP1LMNATSHRKMT2A | |
| Mephenytoin SCHEMBL21766 | 0.78 | CYP2C19 (1.00) | CYP2C19TDP1LMNATSHRKMT2A | |
| SCHEMBL8498625 | 0.76 | KMT2A (0.64) | CYP2C19LMNAKMT2AELANENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12325704-B2 | SRPK1 inhibitors | EXONATE LIMITED (GB) | 2025-06-10 | — | — | US | disclosed |
| US-20220389015-A1 | SRPK1 INHIBITORS | EXONATE LIMITED (GB) | 2022-12-08 | — | — | US | disclosed |
| US-11420969-B2 | SRPK1 inhibitors | EXONATE LIMITED (GB) | 2022-08-23 | — | — | US | disclosed |
| CN-114667498-A | Workflow for generating compounds that are biologically active against specific biological targets | 英科智能有限公司 | 2022-06-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420969-B2 | SRPK1 inhibitors | SRPK1, SRPK3, SRPK2 | CYP2C19 4878/4885TDP1 219/4885LMNA 3977/4885 |
| US-20220389015-A1 | SRPK1 INHIBITORS | SRPK1, SRPK3, SRPK2 | CYP2C19 4878/4885TDP1 219/4885LMNA 3977/4885 |
| US-12325704-B2 | SRPK1 inhibitors | SRPK1, SRPK3, SRPK2 | CYP2C19 4878/4885TDP1 219/4885LMNA 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.